These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38723364)

  • 1. Surgical removal of extended-release buprenorphine depot due to adverse reactions.
    Burton A; DeBona DJ; Handzel M; Kelly-Pisciotti S; Qiao M; Rojek D; Acquisto NM
    Am J Emerg Med; 2024 Jul; 81():127-128. PubMed ID: 38723364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
    D'Onofrio G; Herring AA; Perrone J; Hawk K; Samuels EA; Cowan E; Anderson E; McCormack R; Huntley K; Owens P; Martel S; Schactman M; Lofwall MR; Walsh SL; Dziura J; Fiellin DA
    JAMA Netw Open; 2024 Jul; 7(7):e2420702. PubMed ID: 38976265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.
    Azar P; Schneiderman H; Barron H; Wong JSH; Meyer M; Newman-Azar D; Narimani M; Ignaszewski MJ; Mathew N; Mullen R; Krausz RM; Maharaj AR
    Addict Sci Clin Pract; 2024 Jun; 19(1):50. PubMed ID: 38886826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine implants in medical treatment of opioid addiction.
    Chavoustie S; Frost M; Snyder O; Owen J; Darwish M; Dammerman R; Sanjurjo V
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):799-807. PubMed ID: 28571505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Remission of Opioid Use Disorder in an Adolescent Using Buprenorphine Extended - Release Subcutaneous Injection: A Case Report.
    Schmuhl KK; Golec A; Ebersole AM
    J Adolesc Health; 2024 Jul; 75(1):200-202. PubMed ID: 38402472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
    Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
    JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
    Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
    Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine Treatment for Opioid Use Disorder: An Overview.
    Shulman M; Wai JM; Nunes EV
    CNS Drugs; 2019 Jun; 33(6):567-580. PubMed ID: 31062259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the delivery of buprenorphine for opioid dependence.
    Rosenthal RN; Goradia VV
    Drug Des Devel Ther; 2017; 11():2493-2505. PubMed ID: 28894357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes.
    Kanervo M; Tupola S; Nikkola E; Rantakari K; Kahila H
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():106-110. PubMed ID: 38608352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.
    Vorspan F; Hjelmström P; Simon N; Benyamina A; Dervaux A; Brousse G; Jamain T; Kosim M; Rolland B
    Expert Opin Drug Deliv; 2019 Sep; 16(9):907-914. PubMed ID: 31364884
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictors of availability of long-acting medication for opioid use disorder.
    Shover CL; Humphreys K
    Drug Alcohol Depend; 2019 Nov; 204():107586. PubMed ID: 31593871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
    Tompkins CNE; Neale J; Strang J
    J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.
    Frost M; Bailey GL; Lintzeris N; Strang J; Dunlop A; Nunes EV; Jansen JB; Frey LC; Weber B; Haber P; Oosman S; Kim S; Tiberg F
    Addiction; 2019 Aug; 114(8):1416-1426. PubMed ID: 31013390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged-release buprenorphine formulations: Perspectives for clinical practice.
    Chappuy M; Trojak B; Nubukpo P; Bachellier J; Bendimerad P; Brousse G; Rolland B
    Therapie; 2020; 75(5):397-406. PubMed ID: 32499082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
    Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
    Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New drugs for substitution treatment of opioid dependence. Buprenorphine and 1-alpha-acetylmethadol (LAAM) ].
    Petersen H; Skauge L; Svejsø J; Ege PP
    Ugeskr Laeger; 2000 Nov; 162(48):6553-6. PubMed ID: 11187226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An injection depot formulation of buprenorphine: extended bio-delivery and effects.
    Sigmon SC; Moody DE; Nuwayser ES; Bigelow GE
    Addiction; 2006 Mar; 101(3):420-32. PubMed ID: 16499515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.